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Abstract
The COVID-19 outbreak is posing unprecedented risks and challenges for all communities and health care systems, world-
wide. There are unique considerations for many adult patients with gliomas who are vulnerable to the novel coronavirus 
due to older age and immunosuppression. As patients with terminal illnesses, they present ethical challenges for centers 
that may need to ration access to ventilator care due to insufficient critical care capacity. It is urgent for the neuro-oncology 
community to develop a proactive and coordinated approach to the care of adults with gliomas in order to provide them 
with the best possible oncologic care while also reducing their risk of viral infection during times of potential health care 
system failure. In this article, we present an approach developed by an international multidisciplinary group to optimize 
the care of adults with gliomas during this pandemic. We recommend measures to promote strict physical distancing and 
minimize exposures for patients, address risk and benefit of all therapeutic interventions, proactively develop end-of-life 
plans, educate patients and caregivers, and ensure the health of the multidisciplinary neuro-oncology workforce. This 
pandemic is already changing neuro-oncologic care delivery around the globe. It is important to highlight opportunities 
to maximize the benefit and minimize the risk of glioma management during this pandemic and potentially, in the future.
Key Points
1.  Adult patients with gliomas are at high risk of morbidity and mortality during the COVID-
19 pandemic.
2.  Neuro-oncology teams need to reevaluate the risk and benefit of oncologic therapy in the 
setting of limited health care resources during a pandemic with a highly infectious agent 
that can cause severe human disease.
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The COVID-19 pandemic poses an imminent and extraordi-
nary threat to many adults with gliomas, their support com-
munities, health care workers, and the very health systems 
in which we work around the globe. While much remains to 
be discovered about the novel coronavirus, observations in 
China indicate that 2.3% of patients required ventilator sup-
port and 1.4% of patients died.1 Reports from Italy suggest a 
higher death rate, near 7%, and we may expect geographic 
variation based on populations, testing availability, and 
health systems.2 Higher severity of illness and death appear 
to be associated with older age, diabetes, cardiopulmonary 
disease, and immune depression.3 There is also concern 
that cancer patients and cancer survivors are more likely to 
get infected with the novel coronavirus and are more likely 
to die from complications of COVID-19.4 In addition, during 
times of quarantine and social distancing, cancer patients 
may have difficulty accessing life-extending care and sup-
ports. Asymptomatic spread, high infectivity rate, and rapid 
expansion of disease among individuals in a community 
contribute to exponential growth. With only weeks of lead 
time to recognition that the novel coronavirus is present in a 
new region, our local health care systems are anticipated to 
have insufficient ventilator capacity to manage all patients.5 
Stark choices will need to be made, as in Italy, prioritizing 
interventions for some patients over others.6 The burden on 
the health care system is likely to require difficult consider-
ations for determining medical resource utilization.7 The un-
bearable truth in neuro-oncology is that many adults with 
gliomas, who may be both older and with terminal diag-
noses, may be denied ventilator care in favor of younger 
patients with better chances of long-term survival. Avoiding 
exposure and preventing infection especially during periods 
of viral surge are, therefore, our absolute priorities.
Given this priority, we need to define how we deliver 
care to adults with glioma, consider optimal timing of 
interventions, and determine when the risk of exposure 
to the novel coronavirus or lack of access to the medical 
system to manage treatment-emergent complications may 
exceed the potential benefits of therapy. Here, we present 
suggestions and considerations for an approach to the care 
of adults with gliomas in times of an evolving and unprec-
edented health care crisis and with the recognition that ac-
tual policies will vary between institutions and regions.
Aggressively Promote Physical Distancing 
and Minimize Patient Exposure
In order to limit spread of the virus and protect our broader 
communities, we need to be forceful advocates of physi-
cal distancing and limit all unnecessary interactions for 
our patients. Outpatient visits that are not associated with 
disease-altering interventions should no longer be the rou-
tine. Only patients in whom an in-person examination is 
vital to determine next steps of care should come to a clinic 
appointment. The necessity of seeing patients in person is 
being redefined every day and will need to be individually 
decided between the provider and the patient. Telephone 
and video visits should be utilized to assess patients. In 
both of these settings, trainees, nurses, advanced practice 
providers (APPs), and pharmacists are encouraged to be 
integrated, in order to continue multidisciplinary coordi-
nation of care. A telemedicine visit that includes a neuro-
oncologist, nurse, and APP, for instance, can help minimize 
extra steps of communication and avoid confusion about 
treatment plans. For many clinicians, the thought of seeing 
a patient with newly diagnosed brain tumor or having an 
end-of-life discussion remotely is a difficult, but neces-
sary, transition to maximize the safety and outcomes for 
all stakeholders. It is important to recognize potential bar-
riers for comprehensive remote care, including no or poor 
internet access, language barriers, and low technology lit-
eracy that may preclude effective video visits. Telephone 
care may have to serve as a primary means of clinical 
care and both phone and video translation services can be 
offered remotely. Involving social support services within 
medical centers and communities as well as engaging pa-
tient advocacy groups can help in identifying additional 
resources. In-person visits will still be required when abso-
lutely necessary to inform a specific treatment decision, for 
hands-on therapies, when social circumstances preclude 
adequate care remotely, or when direct care would prevent 
emergency room or primary care visits that could increase 
resource burden on the health care system. These visits 
should be organized to minimize patient interactions to the 
greatest extent possible.
Determine Goals of Care in the Context 
of the Pandemic
We must recognize that for adults with malignant gliomas 
in particular, restrictions on travel and physical distancing 
may be present for the duration of their lives. Discussions 
regarding their life goals, bucket list, and even basic 
interactions with family members are deeply affected by 
our current circumstances. We are also faced with much 
more complicated discussions regarding life-sustaining 
measures. Our intensivists and hospitalists will soon be 
overburdened by patients requiring mechanical ventila-
tion, and it is our responsibility to both our patients and 
health care communities to engage in discussions about 
Importance of the Study
We have compiled an international and multidis-
ciplinary group of experts to guide colleagues in 
neuro-oncology in the urgent decision making that is 
required during the COVID-19 pandemic. Providers 
in neuro-oncology will be required to guide patients 
and health care systems in making care decisions 
for adults with glioma that weigh unprecedented 
risks and health care system limitations.
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life-sustaining therapies for all patients with gliomas prior 
to an acute decline.8 In patients who are likely to die within 
the next 12 months, a clear discussion regarding wishes 
and possibilities for resuscitation and intubation should 
be conducted in the context of requiring mechanical ven-
tilation for COVID-19 and in the context of an acute cancer-
related event. These conversations should be clearly 
documented. In patients who choose against aggressive in-
tervention, a home plan outlining supportive and palliative 
care measures that tries to avoid emergency and inpatient 
visits should be outlined. Patients with longer potential 
for survival should be identified, and this should be docu-
mented along with clear wishes regarding life-sustaining 
therapies. In the unfortunate, yet likely, event that access 
to ventilators is triaged, we cannot assume that emer-
gency medicine physicians and intensivists understand 
that a subset of our patients with brain tumors may have 
a life expectancy of several years or longer. As institutions 
start developing guidelines regarding patient prioritization, 
educating our departmental representatives that some of 
our patients may meet criteria for aggressive measures 
is our unique responsibility. Developing evidence-based 
triage guidelines before we are in a crisis situation should 
be a top priority for all neuro-oncology centers.
It is incumbent on neuro-oncology teams to communi-
cate with their hospital systems regularly and to be aware 
of when inpatient and ventilator needs are expected to 
surge. Recent models suggest that the periods when needs 
exceed ventilator capacity may last for 3 to 6 months, but 
timing of this depends on the specific geographic location 
and local caseload.5,9 It is during this period that our pa-
tients will be at highest risk of contracting the virus, and 
infection in our patients may result in the direst conse-
quences. We should proactively define what constitutes 
necessary care and understand what elements of therapy 
can be deferred until after this period, as well as define 
interventions of uncertain value that do not warrant the 
risk of exposure. Discussion of all treatment plans during 
clinics and tumor boards needs to be done in the context 
of this pandemic, with multidisciplinary assessment of risk 
and benefit for every proposed therapeutic intervention. 
Coordination of care across disciplines, already common-
place for neuro-oncology, is more vital than ever to ensure 
that when patients physically present to a treatment center, 
care is streamlined to minimize exposures.
Assess Risk and Benefit of Therapeutic 
Interventions in Adults with Gliomas
Standard approaches to the oncologic care of patients 
with gliomas need to be immediately reconsidered.10–12 
Table 1 summarizes guidance on how to approach thera-
peutic decisions during this pandemic. Many centers have 
eliminated all elective surgeries and in patients with pre-
sumed benign tumors and tolerable symptoms, surgery 
and any adjuvant radiotherapy should be deferred. Center 
for Medicare and Medicaid Services guidelines to assist 
surgeons and hospitals in their decision to delay surgical 
intervention suggest that surgical interventions for low 
risk cancers be postponed.13 In patients with presumed 
low-grade gliomas and therefore presumed slow growth 
rate, an observational approach with a repeat MR scan in 
3–6 months (depending on clinical variables) rather than 
active treatment or shorter intervals between imaging may 
be optimal. Diagnostic surgery and adjuvant therapy can 
be safely delayed, especially if the patient presents with 
only limited and stable neurological symptoms and fur-
ther tumor growth will not preclude complete resection. 
In patients with imaging features suggestive of high-grade 
gliomas, standard of care maximal safe resection should 
be performed in order to make a definitive diagnosis and 
create a tailored treatment plan, especially in younger 
adults and those with high performance status. In pa-
tients undergoing resections, the use of implanted BCNU 
(carmustine) wafers can still be considered in individual 
cases as this does not involve an additional exposure. In 
older patients with frailty and comorbid conditions, sur-
gical biopsy or resection might need to be abnegated, 
and further treatment strategies may have to be based 
on the radiological findings alone. For all patients, inte-
gration of molecular features, age, extent of resection, 
and performance status are critical to predict prognosis 
and the potential benefit of added therapies. Tools such 
as the European Organisation for Research and Treatment 
of Cancer GBM calculator (https://www.eortc.be/tools/
gbmcalculator/) and the Geriatric 8 (G8) scale can help in 
objective decision making and ensuring that decisions are 
not based on chronologic age alone.14
Isocitrate dehydrogenase–wildtype (IDHwt) gliomas con-
stitute the majority of high-grade tumors in adult neuro-
oncology patients. These tumors can grow rapidly in short 
periods of time, and deferral of therapy beyond the antici-
pated length of the pandemic carries a high risk of tumor 
growth, increased neurological morbidity, and in some 
cases, earlier death. Patients with O6-methylguanine-DNA-
methyltransferase (MGMT) promoter methylated tumors 
are likely to gain the most from temozolomide concurrent 
with radiation and potentially in the adjuvant setting. In 
these cases, depending on patient clinical characteristics, 
the benefit of standard-of-care therapy consisting of a full 
course of radiotherapy and chemotherapy likely exceeds 
the risk of death from COVID-19. Patients receiving tumor 
treatment field therapy need to take precautions to mini-
mize exposures when getting assistance from technicians 
or family members with array placement, and this need 
for frequent contact should be considered in discussions 
with patients about this treatment modality. Even during 
“maximal aggressive” treatment for adults with malignant 
glioma, we should be limiting in-person visits in favor of 
telehealth, performing toxicity checks remotely and only at 
the absolutely required intervals in order to limit patient 
exposure. Conservative dosing in patients who may show 
signs of bone marrow toxicity may help to avoid immu-
nosuppression, consequent inpatient admission, or visits 
for platelet transfusions. Patients who develop viral symp-
toms while undergoing chemotherapy should be tested 
immediately and chemotherapy should be stopped. If the 
patient tests positive for COVID-19, chemotherapy should 
be held until the patient recovers fully from the infection, 
and risks and benefits of therapy should be reevaluated at 
that time. The most common laboratory finding at presen-
tation of COVID-19 in China was lymphopenia, occurring 








in more than 80% of patients,1 and for patients receiving 
temozolomide and with suspected infection, this labora-
tory finding will need to be interpreted in the context of 
treatment-induced lymphopenia.1
Procedures to maintain safety of patients and health care 
workers during radiation therapy have been developed and 
should be followed.15 Radiation therapy poses a unique 
challenge as daily visits result in frequent exposures for 
patients and staff and cannot be conducted remotely. Extra 
precautions may include screening patients for viral symp-
toms, restricting caregivers from accompanying patients, 
and using protective equipment for patients and medical 
staff. Institutional policies are required to protect the safety 
of both patients and health care workers. In the event that a 
patient develops viral symptoms during radiation therapy, 
a low threshold for testing is warranted. Radiation therapy 
can continue in patients with suspected or confirmed co-
ronavirus infection as long as their disease is mild and the 
radiation facility has measures in place to prevent spread 
to other patients and staff. These measures include concur-
rent use of appropriate personal protective equipment for 
both staff and patients as well as thorough disinfection of 
all surfaces between patients. In cases where patients have 
significant viral symptoms, treatment should be halted and 
resumed only after the patient recovers.
Patients with MGMT-unmethylated gliomas may not de-
rive as much benefit from incorporation of temozolomide, 
and based on age and performance status a multidiscipli-
nary team must work with patients and their families to 
determine the optimal course of treatment. In these situ-
ations, we may need to consider shorter courses of radio-
therapy and avoid concurrent and adjuvant chemotherapy.
In older patients, interventions that may expose them to the 
novel coronavirus may result in more harm than good. Shorter 
radiation courses should be discussed and, at times, even 
1-week courses of radiation therapy16 may need to be initiated. 
Although there is survival benefit in older patients from the use 
of temozolomide, the benefits are modest and largely confined 
to patients with MGMT-methylated tumors.17 For older patients 
with unmethylated MGMT glioblastoma, the risk of morbidity 
from treatment, immunosuppression, and viral exposure may 
be considerable, and, for most, withholding temozolomide is a 
reasonable choice.
Patients with IDH-mutated (IDHmt) gliomas have more indo-
lent disease, and some interventions may be deferred. IDHmt 
glioblastoma remains aggressive, and decision making will 
likely be similar to that of patients with IDHwt tumors. Patients 
with World Health Organization grade II and grade III IDHmt 
gliomas should delay therapy, especially those with 1p/19q 
codeletion. These decisions will need to be made individu-
ally, balancing the potential for long-term survival with age, 
comorbidities, the societal directives for social distancing, risks 
to patient families, and the added bone marrow toxicities of re-
gimens that incorporate procarbazine, CCNU, and vincristine. 
In most oligosymptomatic patients with favorable prognostic 
markers, it will be both reasonable and feasible to defer therapy 
for 6 months or more without evidence of worse outcome.
In high-grade IDHwt gliomas, there is no clear sur-
vival benefit for treatment at recurrence, and any thera-
peutic interventions need to be thoughtfully considered. 
Bevacizumab does not meaningfully improve survival and 
its use should be reserved for the palliation of neurologic 
symptoms due to cerebral edema. Regimens that increase 
the interval between doses based on the known half-life of 
the drug (6‒8 wk) should be considered. Therapies in re-
current GBM have no clear evidence of survival benefit 
and should be weighed against the risks of immunosup-
pression, hospitalization from complications, and potential 
exposure to the novel coronavirus through required inter-
actions to receive these interventions. Increase in visits 
and health care utilization potentially increases risk of ex-
posure and immunosuppression and might result in more 
severe infection when exposure does occur.
Today, surveillance imaging in gliomas varies widely 
and is largely directed by consensus opinion and indi-
vidual practice patterns. Each MR scan results in addi-
tional potential viral exposures to glioma patients, other 
patients, and radiology staff. In patients with high-grade 
gliomas who are asymptomatic or not newly symptomatic 
and where imaging findings are unlikely to change man-
agement, scans should be delayed. In lower grade tumors 
with stable symptoms, the interval between scans can be 
extended safely even if they are on active therapy. Patients 
who do need imaging should be encouraged to do this 
closer to home to avoid travel and to avoid exposures in 
hospital settings or larger, specialized centers.
Access to and enrollment on clinical trials is a core 
part of the care of patients with high-grade gliomas. 
The United States FDA guidance allows for increased 
flexibility and decreased regulatory burden to modify 
protocols and procedures in order to ensure patient 
safety.18 Each institution, trial, and sponsor has some 
leeway to approach this based on circumstances, but 
many are halting new enrollments on clinical trials un-
less they are specifically related to COVID-19 or con-
sidered to have a high likelihood of being a lifesaving 
therapy for a given condition. In addition, the Code of 
Federal Regulations (CFR) allows great flexibility when 
deviations may be required to avoid or eliminate “ap-
parent immediate hazards” (eg, 21 CFR 56.108(a)(4) and 
45 CFR Part 46.108 (a) (3) (iii)). However, it is impera-
tive to engage the local institutional review board (IRB)/
ethics committee to align interpretations and processes, 
document carefully in the medical and research records 
the rationale for actions taken, and log deviations to the 
investigational plan for reporting to the IRB and spon-
sors after the emergency situation has ended.
For recurrent gliomas where there is no standard 
proven therapy, clinical trials are an important option for 
patients, but protocols may require modification to min-
imize exposures. Frequent visits must be avoided and 
travel to distant locations for trial enrollment is discour-
aged. Phase I  trials with safety and dose-finding aims 
require frequent visits, testing, and blood draws and 
are likely to present more risks than benefit for partici-
pants, health care providers, and clinical research staff. 
Phase II and III studies, with survival aims, may remain 
an option, but protocols will need to be modified to min-
imize any visits that are not required for patient safety 
and benefit. This pandemic highlights the need to rap-
idly develop assessments that can be performed effec-
tively and safely through remote means. Nontherapeutic 
clinical research to inform our understanding of natural 
history, supportive care, quality of life, and outcomes 
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for adults with glioma during the novel coronavirus pan-
demic remains important. However, all in-person visits 
and assessments for these studies should be eliminated 
to only critical visits. Neuro-oncology teams need to be-
come acutely aware of the frequently changing local IRB 
and cancer center policies regarding clinical research.
Educate Patients and Caregivers About 
COVID-19
We cannot assume that patients and caregivers have the same 
understanding of COVID-19 as health care providers. Patients 
with gliomas are more likely to interact with their neuro-
oncology team during this pandemic than their own primary 
care providers, and at each visit we must emphasize the im-
portance of hand-washing and the need for and meaning of 
social distancing, and we should partner with patients to trou-
bleshoot ways in which they can minimize unnecessary inter-
actions. They need to know that they may be at exceptional 
risk if infected, and all measures to avoid infection must be 
recommended. We also need to acknowledge the social isola-
tion that many of our patients may be experiencing, and any 
extra time we take to engage with our patients and their care-
givers, even in remote visits, may be invaluable. We must re-
main accessible to our patients by phone to be able to triage the 
presentation of new symptoms to make sure that our patients 
only visit the emergency department when absolutely neces-
sary. This will prevent unnecessary exposure for our patients 
and will free valuable time for emergency medicine physicians 
and staff. Referral of patients and families to publicly available 
information should be encouraged (such as https://www.
cancer.gov/contact/emergency-preparedness/coronavirus).
Ensure the Health and Safety of the 
Neuro-Oncology Workforce
Weekly communal gatherings such as multidisciplinary brain 
tumor conferences need to be reorganized and conducted 
with videoconferencing technology. Most neuro-oncology 
programs have only a few clinicians and it is imperative that 
social distancing mechanisms within the neuro-oncology pro-
gram be instituted. If an entire neuro-oncology workforce is 
sick or quarantined at a given institution, patient care will be 
interrupted. Measures to separate, reexamine co-location of 
clinical services, and eliminate all in-person meetings should 
be initiated. We may expect that up to 25‒40% of the workforce 
will be infected or quarantined at a single time. For neuro-
oncology providers with comorbid conditions predisposing 
to a higher severity illness, consideration should be given to 
rearranging duties to allow their work to focus on remote care 
and administrative responsibilities. Centers with single neuro-
oncology providers should partner with larger institutions that 
can help in delivering remote care and assessing patients in 
remote tumor boards. Collaboration across our field is critical.
Recognize the Transformative Effects of 
the COVID-19 Pandemic
The COVID-19 pandemic is unprecedented in our lifetimes 
and our approach to the care for our patients may change 
  
Table 1. Recommendations for adjuvant therapy in patients with gliomas during COVID-19 pandemic
Patients with Newly Diagnosed IDHwt Gliomas
• MGMT methylated tumors
 ◦Standard of care therapy with precautions to minimize exposures
• MGMT unmethylated tumors
 ◦Consider shorter courses of radiation therapy
 ◦Avoid temozolomide
 ◦Supportive care alone in older, poor performing patients
Patients with Newly Diagnosed IDHmt Gliomas
• Glioblastoma and anaplastic astrocytoma
 ◦Standard of care therapy with precautions to minimize exposures
• Low grade astrocytoma and 1p/19q codeleted tumors
 ◦Consider delaying all therapies in asymptomatic patients
 ◦Case by case decisions in symptomatic patients
Patients with Recurrent gliomas
• IDHwt high-grade gliomas
 ◦Bevacizumab only in cases for palliation of neurologic symptoms with precautions to minimize exposures
 ◦Phase II or III trials with precautions to minimize exposures
 ◦Avoid all surgical, radiation, and chemotherapeutic interventions with no evidence for survival benefit
• All other recurrent tumors
 ◦Case by case decisions with consideration of delaying therapy
  








rapidly. Our guidance is based on circumstances today 
and as we understand them, but we need to acknowl-
edge that this pandemic may stretch resources in some 
regions in ways that we cannot imagine and we need to 
prepare for scenarios where treatment of patients with 
incurable diseases consists of the absolute minimum. As 
neuro-oncology providers, we are not on the front lines 
of the most critical and dangerous aspects of clinical care, 
but the approach we take and decisions we make will 
substantively influence our patients, our colleagues, and 
our health systems. It is important that we remain proac-
tive—as our experiences and circumstances change, we 
are the only ones who know best the needs of adults with 
gliomas. Despite the dire circumstances and the serious 
toll on human life, there are opportunities here to trans-
form the care for our patients. Rapid adoption of technolo-
gies will allow us to move forward with telehealth, remote 
tumor boards, and incorporation of remote visits in clin-
ical research. These measures can have a profound impact 
on our ability to manage patients who live far from estab-
lished neuro-oncology centers. Finally, as we are faced 
with decisions on what tests, therapies, and images we 
can delay, we should welcome the opportunity to have a 
dialogue about and redefine what is truly necessary for the 
health care of our patients with gliomas. As a profession, 
we are used to complexity, uncertainty, and tragedy—and 
the resilience we have developed from the care of our pa-
tients will serve us well.
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